This triple-action mechanism distinguishes it from existing approved therapies such as semaglutide (GLP-1 receptor agonist only) or tirzepatide (GLP-1/GIP dual agonist)
FDA Recall Announcement Dextroamphetamine Saccharate (Adderall XR Generic) Recall by Granules Pharmaceuticals Over 50,000 bottles of Attention-deficit/hyperactivity disorder (ADHD) treatment Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate extended-release capsules have been recalled by Granules Pharmaceuticals because of an unknown impurity found in the product during a stability study
Find out if you fit our law firms criteria for an Trulicity claim
The antiatherogenic effect of the GLP-1 class is widely described in the literature, but we still need more clinical evidence on the cardiovascular impact in patients with diabetes
Like all medications, it comes with some risks, but with the right plan and support, most side effects can be managed or avoided
Researchers with concerns about cardiovascular parameters should establish baseline readings before beginning any protocol and track them at regular intervals throughout treatment
